Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 19592491 
Jang SW, et al. (2009) Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell cycle and cell death in neurons. J Biol Chem 284, 24512-25 19592491
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S1180-p - acinus (human)
Orthologous residues
acinus (human): S1180‑p, acinus iso2 (human): S453‑p, acinus iso5 (human): S1167‑p, acinus (mouse): S1179‑p, acinus iso5 (mouse): S393‑p, acinus (rat): S1180‑p
Characterization
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE SRPK2 (human)

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
LY293002 EGF inhibit treatment-induced increase
wortmannin EGF inhibit treatment-induced increase
GF109203X EGF no effect upon treatment-induced increase
PD98059 EGF no effect upon treatment-induced increase

T492-p - SRPK2 (human)
Orthologous residues
SRPK2 (human): T492‑p, SRPK2 (mouse): T485‑p, SRPK2 (rat): T485‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE Akt1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (human) transfection of wild-type enzyme, phospho-motif antibody, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
LY293002 EGF inhibit treatment-induced increase
wortmannin EGF inhibit treatment-induced increase
GF109203X EGF no effect upon treatment-induced increase
PD98059 EGF no effect upon treatment-induced increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced, intracellular localization, molecular association, regulation
 Effect of modification (process):  cell cycle regulation, transcription, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
14-3-3 beta (human) Induces co-immunoprecipitation
14-3-3 epsilon (human) Induces co-immunoprecipitation
 Comments:  nuclear translocation of SRPK2 is blocked by 14-3-3

S473-p - Akt1 (mouse)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  'neuron, cortical'
 Cellular systems studied:  cell lines, primary cultured cells
 Species studied:  mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ischemia increase

T485-p - SRPK2 (mouse)
Orthologous residues
SRPK2 (human): T492‑p, SRPK2 (mouse): T485‑p, SRPK2 (rat): T485‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  'neuron, cortical'
 Cellular systems studied:  cell lines, primary cultured cells
 Species studied:  mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ischemia increase

T485-p - SRPK2 (rat)
Orthologous residues
SRPK2 (human): T492‑p, SRPK2 (mouse): T485‑p, SRPK2 (rat): T485‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  'neuron, cortical'
 Cellular systems studied:  cell lines, primary cultured cells
 Species studied:  mouse, rat
Downstream Regulation
 Effect of modification (process):  apoptosis, altered


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.